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Cell of Origin
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in western countries. Although several hypotheses have been proposed, the precise cell of 
origin of CLL is still debated. CLL tumor cells typically express CD19, CD5, CD23, and the low-intensity surface immunoglobulins IgM and IgD. The identification of two subsets 
of CLL, mutated (mCLL) and unmutated (uCLL), according to immunoglobulin heavy (IGH) chain variable gene segment (IGHV ) mutational status, led to the hypothesis that 
mCLL might derive from a cell that has experienced the germinal center, where the somatic hypermutation occurs. On the other hand, a naive B cell could represent the normal 
counterpart of uCLL. However, gene expression profiling studies have shown that mCLL and uCLL are transcriptionally overlapping and clearly distinct from normal CD5+ cells. 
This observation suggests that both subsets, not only mCLL, might originate from antigen-experienced cells. Accordingly, it has been postulated that mCLL derives from a 
CD5+CD27+ memory B cell, whereas uCLL tends to be more similar to CD5+CD27− cells that can be activated by antigenic stimuli in a T cell-independent fashion under some 
circumstances.
Interestingly, recent findings have substantially revolutionized the concept that CLL is a disease arising from a mature B cell, indicating the involvement of a hematopoietic 
stem cell in the transformation process. Through the use of deep sequencing of flow-sorted cells from mCLL and uCLL patients, acquired mutations affecting known lymphoid 
oncogenes (including SF3B1 and NOTCH1) were observed in both myeloid progenitors (CD34+) and CLL tumor cells, suggesting that driver mutations probably occur early in the 
evolutionary biography of CLL. According to the hypothesis that the cell of origin is a common hematopoietic precursor, the naive B cell, harboring clonal passenger mutations, 
would enter the lymph node, where secondary genetic events triggered by B cell receptor (BCR) activation may favor definitive clonal transformation and expansion of a CD5+ 
B cell. However, mutated genes in CLL B cells cluster in a few pathways (i.e., NOTCH1 signaling, mRNA splicing processing and transport, DNA damage response, and innate 
inflammatory response) that are differently represented in mCLL and uCLL.
Evolution, Progression, and Transformation
The progression of CLL disease matches the paradigm of clonal evolution elapsing from the initiating event(s), following malignant transformation of a CD5+ B cell through to 
Richter’s transformation. Monoclonal B cell lymphocytosis (MBL), an indolent condition, is believed to precede overt CLL. The next step to the CLL stage is driven by stimulation 
of the B cell receptor by microenvironmental antigens. Subsequently, the occurrence of secondary genomic abnormalities yielding clonal heterogeneity within tumors leads to 
progressed CLL. Finally, the selection and expansion of highly fit subclones, those bearing driver mutations, in response to intrinsic (genetic instability) or extrinsic (chemo-
therapy) pressures is responsible of disease progression, Richter’s transformation, and chemorefractoriness.
Prognostic Factors
Over the last two decades, several studies have shown a relationship between the clinical heterogeneity of CLL and the presence of specific patient- or disease-associated 
features. Several cytogenetic abnormalities and IGHV mutational status have been validated as predictors of clinical evolution and chemoresistance. Most recently, specific 
IGHV gene usage and stereotyped CDR3, ZAP70, and CD38 expression levels have been associated with a higher susceptibility of BCR to be stimulated by antigen and thus 
with an increased predisposition to cell proliferation and clonal expansion.
MicroRNAs (miRNAs), small regulatory noncoding RNAs, are causally involved in CLL initiation (cluster of miR-15a and miR-16-1), progression (miR-21, miR-29 family, or miR-
34 family), and resistance to therapy (miR-155 and miR-181 family). The availability of next-generation sequencing data has provided us with new insights into the understanding 
of CLL biology and clinical heterogeneity. NOTCH1, BIRC3, MYC, SF3B1, and MYD88 abnormalities have emerged as key drivers in CLL progression and, therefore, as powerful 
tools to define prognosis and targets for therapy in the near future.
Therapy: From Bench to Bedside
Although chemoimmunotherapy is still recommended for the treatment of certain CLL patients, new compounds that specifically target cellular pathways that are abnormally 
regulated in CLL tumor cells have been approved for the treatment of patients with CLL. Many more new molecules with a variety of targeted mechanisms of action are in various 
stages of preclinical and clinical development. Immunomodulatory agents and chimeric-antigen receptor (CAR) T cells have also shown marked antileukemic activity in patients 
with CLL, which underscores the importance of the immune system and the microenvironment in disease control. Additionally, antisense and anti-miRNA molecules are opening 
new avenues for the treatment of CLL.
Mouse Models
Several mouse models reproducing different subtypes of CLL have been developed. Transgenic mice overexpressing TCL1 in B cells (Eµ-TCL1 mice) recapitulate aggressive 
disease, whereas mir-15a/16-1-deleted mice and the New Zealand Black strain mimic indolent CLL. Mouse models represent an important tool to help decipher the role of gene 
mutations in CLL and allow preclinical testing of new compounds.
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